Should I buy or sell Compass Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CMPX shares. View CMPX analyst ratings or view top-rated stocks .

What is Compass Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 1 year price targets for Compass Therapeutics' stock. Their CMPX share price targets range from $8.00 to $10.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 473.2% from the stock's current price. View analysts price targets for CMPX or view top-rated stocks among Wall Street analysts .

How have CMPX shares performed in 2024?

Compass Therapeutics' stock was trading at $1.56 at the start of the year. Since then, CMPX shares have increased by 0.6% and is now trading at $1.57. View the best growth stocks for 2024 here .

Are investors shorting Compass Therapeutics?

Compass Therapeutics saw a decline in short interest in March. As of March 31st, there was short interest totaling 1,620,000 shares, a decline of 13.8% from the March 15th total of 1,880,000 shares. Based on an average daily trading volume, of 485,500 shares, the short-interest ratio is presently 3.3 days. Approximately 2.0% of the company's shares are sold short. View Compass Therapeutics' Short Interest .

When is Compass Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CMPX earnings forecast .

How were Compass Therapeutics' earnings last quarter?

Compass Therapeutics, Inc. (NASDAQ:CMPX) released its earnings results on Thursday, March, 21st. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02.

When did Compass Therapeutics IPO?

Compass Therapeutics (CMPX) raised $50 million in an initial public offering (IPO) on the week of November 16th 2020. The company issued 9,000,000 shares at $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager.

How do I buy shares of Compass Therapeutics?

Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CMPX

Compass Therapeutics (CMPX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CMPX Stock Alerts

$1.57

-0.01 (-0.63%)

(As of 04:15 PM ET)

Compare

Today's Range: $1.53
▼
$1.64
50-Day Range: $1.34
▼
$2.29
52-Week Range: $1.15
▼
$3.62

Volume: 718,708 shs
Average Volume: 499,996 shs
Market Capitalization: $216.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Get Compass Therapeutics alerts:

Compass Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 473.2% Upside
$9.00 Price Target
Short Interest: Healthy
1.97% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.61
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.48) to ($0.50) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.22 out of 5 stars

Medical Sector

331st out of 930 stocks

Biological Products, Except Diagnostic Industry

45th out of 153 stocks

3.5

Analyst's Opinion

Consensus Rating
Compass Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Compass Therapeutics has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.97% of the float of Compass Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Compass Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Compass Therapeutics has recently decreased by 13.83%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Compass Therapeutics does not currently pay a dividend.
Dividend Growth
Compass Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CMPX.

3.1

News and Social Media Coverage

News Sentiment
Compass Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Compass Therapeutics this week, compared to 1 article on an average week.
Search Interest
5 people have searched for CMPX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
MarketBeat Follows
3 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Compass Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
30.00% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.48) to ($0.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Compass Therapeutics is -4.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Compass Therapeutics is -4.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Compass Therapeutics has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Compass Therapeutics Stock (NASDAQ:CMPX)

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

CMPX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CMPX Stock News Headlines

April 12, 2024 | globenewswire.com

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

April 11, 2024 | investing.com

Compass Therapeutics reports potential in tumor treatment

April 16, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 10, 2024 | finance.yahoo.com

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

April 10, 2024 | globenewswire.com

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

April 9, 2024 | globenewswire.com

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

March 25, 2024 | markets.businessinsider.com

Compass Therapeutics: A Strong Buy on Promising Clinical Pipeline and Strategic Milestones

March 24, 2024 | investorplace.com

3 Penny Stocks With the Power to 10X Your $1K Investment

April 16, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 22, 2024 | markets.businessinsider.com

Compass Therapeutics’ Strategic Advancements and Strong Financials Prompt Buy Rating

March 21, 2024 | globenewswire.com

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

March 12, 2024 | finance.yahoo.com

With 52% ownership of the shares, Compass Therapeutics, Inc. (NASDAQ:CMPX) is heavily dominated by institutional owners

February 29, 2024 | globenewswire.com

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

February 28, 2024 | finance.yahoo.com

Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial

February 8, 2024 | msn.com

Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know

February 2, 2024 | morningstar.com

Compass Therapeutics Inc Ordinary Shares

January 31, 2024 | finance.yahoo.com

We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate

January 5, 2024 | finance.yahoo.com

Compass Therapeutics Provides Corporate Update

December 20, 2023 | finance.yahoo.com

Compass Therapeutics Insider Ups Holding During Year

November 17, 2023 | finance.yahoo.com

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 17, 2023 | finance.yahoo.com

Compass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate Developments

November 14, 2023 | msn.com

Compass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

November 3, 2023 | markets.businessinsider.com

TD Cowen Keeps Their Buy Rating on COMPASS Pathways (CMPS)

September 27, 2023 | theglobeandmail.com

Instrument Name Compass Therapeutics Inc Instrument Symbol (CMPX-Q)

August 24, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation

August 3, 2023 | msn.com

HC Wainwright & Co. Reiterates Compass Therapeutics (CMPX) Buy Recommendation

August 3, 2023 | msn.com

Compass Therapeutics GAAP EPS of -$0.09

See More Headlines

Receive CMPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CMPX
CUSIP: N/A
CIK: 1738021
Web: www.compasstherapeutics.com
Phone: 617-500-8099
Fax: N/A
Employees: 32
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.00
High Stock Price Target: $10.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +473.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,490,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -26.07%
Return on Assets: -24.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.73
Quick Ratio: 19.73

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.17 per share
Price / Book: 1.34

Miscellaneous

Outstanding Shares: 137,590,000
Free Float: 96,312,000
Market Cap: $216.02 million
Optionable: Not Optionable
Beta: 0.78

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Vered Bisker-Leib M.D. (Age 52)
MBA, Ph.D., Chief Executive Officer
Comp: $806.43k
Dr. Thomas J. Schuetz M.D. (Age 63)
Ph.D., Co-Founder, President of Research & Development and Vice Chair
Comp: $829.56k
Mr. Neil L. Lerner CPA (Age 57)
Vice President of Finance
Mr. Jonathan Anderman J.D.
VP, Head of Legal & Corporate Secretary
Anna Gifford
Communications Manager
Dr. Minori Rosales M.D. (Age 61)
Ph.D., Senior VP & Head of Clinical Development
Ms. Karin Herrera B.A.
VP & Head of Clinical Operations
Dr. James Kranz Ph.D.
VP and Head of Chemistry Manufacturing & Controls

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CMPX Stock Analysis - Frequently Asked Questions

Should I buy or sell Compass Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CMPX shares.
View CMPX analyst ratings or view top-rated stocks.
What is Compass Therapeutics' stock price target for 2024?: 2 Wall Street analysts have issued 1 year price targets for Compass Therapeutics' stock. Their CMPX share price targets range from $8.00 to $10.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 473.2% from the stock's current price.
View analysts price targets for CMPX or view top-rated stocks among Wall Street analysts.
How have CMPX shares performed in 2024?: Compass Therapeutics' stock was trading at $1.56 at the start of the year. Since then, CMPX shares have increased by 0.6% and is now trading at $1.57.
View the best growth stocks for 2024 here.
Are investors shorting Compass Therapeutics?: Compass Therapeutics saw a decline in short interest in March. As of March 31st, there was short interest totaling 1,620,000 shares, a decline of 13.8% from the March 15th total of 1,880,000 shares. Based on an average daily trading volume, of 485,500 shares, the short-interest ratio is presently 3.3 days. Approximately 2.0% of the company's shares are sold short.
View Compass Therapeutics' Short Interest.

When is Compass Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CMPX earnings forecast.
How were Compass Therapeutics' earnings last quarter?: Compass Therapeutics, Inc. (NASDAQ:CMPX) released its earnings results on Thursday, March, 21st. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02.
When did Compass Therapeutics IPO?: Compass Therapeutics (CMPX) raised $50 million in an initial public offering (IPO) on the week of November 16th 2020. The company issued 9,000,000 shares at $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager.
How do I buy shares of Compass Therapeutics?: Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMPX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Compass Therapeutics (CMPX) Stock Price, News & Analysis

Compass Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Compass Therapeutics Stock (NASDAQ:CMPX)

CMPX Stock Price History

CMPX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

CMPX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™